Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 May 2021Website:
http://www.sentibio.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
SNTI Latest News
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (“CIRM”).
Shares expected to begin trading on split-adjusted basis on July 18, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024
Senti Biosciences (NASDAQ: SNTI ) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company's shares this morning. That has more than 8.5 million shares of SNTI stock changing hands as of this writing.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:
Senti Biosciences, Inc. (SNTI) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.86 per share a year ago.
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
What type of business is Senti Biosciences?
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
What sector is Senti Biosciences in?
Senti Biosciences is in the Healthcare sector
What industry is Senti Biosciences in?
Senti Biosciences is in the Biotechnology industry
What country is Senti Biosciences from?
Senti Biosciences is headquartered in United States
When did Senti Biosciences go public?
Senti Biosciences initial public offering (IPO) was on 26 May 2021
What is Senti Biosciences website?
https://www.sentibio.com
Is Senti Biosciences in the S&P 500?
No, Senti Biosciences is not included in the S&P 500 index
Is Senti Biosciences in the NASDAQ 100?
No, Senti Biosciences is not included in the NASDAQ 100 index
Is Senti Biosciences in the Dow Jones?
No, Senti Biosciences is not included in the Dow Jones index
When was Senti Biosciences the previous earnings report?
No data
When does Senti Biosciences earnings report?
The next expected earnings date for Senti Biosciences is 13 November 2024